pilot study use proteomic technology explore glomerular alteration detectable early stage hn aim identification protein signature predict progress higher severity stage therefore investigate glomerular proteome norwegian cohort adult patient hn include patient without severity progression nonprogressors np progression towards esrd progressors p. importantly carefully microdissected glomerulus use test sample particular glomerulus moderate sclerosis exclude analysis avoid skew result towards composition glomerulosclerosis tissue best knowledge first study glomerular protein biomarkers hn progression adult caucasian patient n 17 biopsyproven diagnosis benign hn angionephrosclerosis norwegian kidney biopsy registry nkbr include study base follow criterion time kidney biopsy age 40 year ii primary systemic kidney disease diabetes mellitus glomerulonephritis vasculitis iii egfr 30 mlmin1.73 ckdepi formula iv absence nephrotic nephritic syndrome clinical indication biopsy v diagnosis treat untreated arterial hypertension due easier access store biopsy material include patient haukeland university hospital importantly however patient fully representative total adult norwegian population receive diagnosis kidney biopsy patient cohort n 17 divide two group main clinical laboratory characteristic patient report table 1. first group include patient progress endstage renal disease esrd within followup period indicate refer progressors p n 8. thereby subject progression esrd within 3 year exclude think individual likely additional different disease entity cause least contribute rapid decrease kidney function display ckd stage 3 time diagnosis second group include patient stable disease define absence progression esrd death nonprogressors np n 9. followup time group average 22 year range 1527. patient match gfr 10 ml min1.73 age 10 year nkbr receive report treat physician throughout entire country patient reach ckd 5 andor start renal replacement therapy way could identify progressors p norwegian unique personal identification number already include nkbr time kidney biopsy thereafter find match non progressors able collect information patient electronic health record paper chart 14 17 subject throughout study followup time far able collect respective data even distribution progressors p non progressors np also regard smoke alcohol intake well expect difference serum creatine level time two study group data show furthermore patient uniformly treat division nephrology haukeland university hospital accord national guideline hypertension treatment publish helsedirektoratet norwegian ministry health 6. subject 13 antihypertensive medication predominant use angiotensinconverting enzyme inhibitor acei angiotensin receptor blocker arb kidney biopsy core obtain 1990 1998 store formalinfixed paraffinembedded ffpe tissue cut microtome 10 micrometer thick section section mount polyethylene naphthalate slide membraneslide 1.0 pen carl zeiss microimaging gmbh g02ttingen germany deparaffinized stain hematoxylin eosin since pen slide suffer poor morphology due lack cover glass parallel section stain periodic acid schiff pa place standard glass slide cover glass use select tissue include study 31 102 mean n 79 glomerular crosssections without severe morphological damage define visible mild glomerulosclerosis low resolution microscopy laser microdissected palm microbeam zeiss collect cap specialize tube adhesivecap 500 clear zeiss describe previous study 5. protein extract trypsinized use filteraided sample preparation fasp protocol describe detail elsewhere 7. briefly microdissected sample suspend 10 08l lysis buffer 0.1 tris ph 8 0.1 dithiothreitol dtt 4 sodium dodecyl sulfate sd heat 99 °c 60 min heat sample strong detergent sd important increase protein yield formalinfixed paraffinembedded sample 8. next perform consecutive wash step use 30 kda filter microcon ym30 millipore remove sd digest protein trypsin overnight elute digest peptide desalt use oasis hlb 08elution plate water milford usa freezedried store 20 °c analysis lyophilize peptide dissolve 2 acn0.1 fa analyze qexactive hf thermo scientific mass spectrometer connect dionex ultimate ncr3500rs lc system sample trap precolumn dionex acclaim pepmap 100 2 cm × 75 08m i.d 3 08m c18 bead load buffer 0.1 tfa flowrate 5 08lmin 5 min separation reverse phase chromatography pepmap rslc 25 cm × 75 08m i.d easyspray column pack 2 08m c18 bead flow 200 nlmin solvent b 0.1 fa volvol water 100 acn respectively gradient composition 5 b trap 5 min follow 58 b 30 835 b next 134.5 min 3590 b 15 min wash condition column perform 15 min treatment 90 b 20 min condition 5 b. m instrument equip easyspray ion source thermo scientific operate ddamode datadependentacquisition instrument control perform qexcative hf tune 2.4 xcalibur 3.0. m spectrum acquire scan range 3751500 mz resolution r 120,000 mz 200 automatic gain control agc target 3e6 maximum injection time 100 ms. 12 intense elute peptide intensity threshold 5e4 charge state 2 higher sequentially isolate target agc value 1e5 resolution r 30,000 110 m normalize collision energy 28. isolation window set 1.6 mz isolation offset 0.3 dynamic exclusion 25 s. lockmass internal calibration also use raw proteomics data lcm analysis process use freely available maxquant software v1.6.8.0 9 use recommend set labelfree quantification 10. identify feature search human reference proteome database download 20190625 uniprot.org mass spectrometry proteomics data deposit proteomexchange consortium via pride 11,12,13 partner repository dataset identifier pxd026709 raw data consist peptide information 2934 protein protein least 2 unique peptide n 2419 consider analysis exclude protein 40 miss value either p np group leave 1870 protein 4 le miss value np group n 9 3 le miss value p group n 8 analysis follow step perform jmp genomics software www.sas.com raw data log2 transform miss value impute per group use multivariate normal imputation shrinkage estimation covariance result data normalize use quantile normalization univariate analysis calculate oneway analysis variance anova shrink variance use empirical bay without standardization intial threshold significance combine criterion absolute fold change fc ≥ 1.5 p ≤ 0.05. pathway analysis perform qiagen ingenuity pathway analysis ipa content version 62089861. ipa regulation zscore algorithm use predict direction change give function increase decrease positive zscore indicate activate state whereas negative zscore indicative inhibition ipa suggest zscores larger 2 smaller 2 significant gene set enrichment analysis gsea use protein symbol run